• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by INVENTIVA

< Previous 1 2 Next >
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
May 05, 2025
From INVENTIVA
Via GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
April 30, 2025
From INVENTIVA
Via GlobeNewswire
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
April 30, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
April 24, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
April 15, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
April 01, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva reports its 2024 full year results and provides a business update
March 26, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
March 19, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
February 26, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
February 20, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
February 10, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
January 29, 2025
From INVENTIVA
Via GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
January 24, 2025
From INVENTIVA
Via GlobeNewswire
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
January 22, 2025
From INVENTIVA
Via GlobeNewswire
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
December 16, 2024
From INVENTIVA
Via GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
December 12, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva reports 2024 Third Quarter Financial Information¹
November 21, 2024
From INVENTIVA
Via GlobeNewswire
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
November 20, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
November 15, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
October 30, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
October 21, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
October 14, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
October 14, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
October 14, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
September 25, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
July 31, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
July 25, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva announces a €20.1 million issuance of royalty certificates
July 18, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
July 05, 2024
From INVENTIVA
Via GlobeNewswire
< Previous 1 2 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap